Document:

Exhibit 10.31

    PROCESS
      DEVELOPMENT AGREEMENT

     

    THIS
      PROCESS DEVELOPMENT AGREEMENT (this “Agreement”)
      is
      entered into as of the 3rd day of May, 2006 (“Effective
      Date”),
      by
      and between Genentech, Inc., a Delaware corporation with an office at 1 DNA
      Way,
      South San Francisco, California 94080-4990 (“Genentech”),
      and
      ImmunoGen, Inc., a Massachusetts
      corporation with corporate headquarters at 128 Sidney Street, Cambridge, MA
      02139 (“ImmunoGen”).
      In
      this Agreement, Genentech and ImmunoGen each may be referred to individually
      as
      a “Party”
and
      together as the “Parties.”

     

    BACKGROUND

     

    A. Genentech
      and ImmunoGen are parties to the following agreements: that certain License
      Agreement dated as of May 2, 2000, and amendments thereto (the “License
      Agreement”);
      that
      certain Heads of Agreement, dated as of May 2, 2000, as amended (as so amended,
      the “Heads
      of Agreement”);
      that
      certain Process Development Heads of Agreement, dated as of June 29, 2001,
      and
      amendments thereto, including that certain Amendment No.1 dated November 15,
      2002 (the “PD
      Heads of Agreement”);
      that
      certain Manufacturing and Supply Agreement dated as of January 11, 2005, and
      amendments thereto (the “Clinical
      Supply Agreement”);
      that
      certain Development Agreement dated as of June 1, 2004, and amendments thereto
      (the “Development
      Agreement”);
      and
      the Quality Services Agreement dated as of June 30, 2005 (the “Quality
      Services Agreement”)
      (the
      License Agreement, the Heads of Agreement, the PD Heads of Agreement, the
      Clinical Supply Agreement, the Development Agreement and the Quality Services
      Agreement, collectively the “Existing
      Agreements”).
      

    

    B. ImmunoGen
      will develop a commercial-scale process for manufacturing the HER2 ADC, and
      Genentech will assist and compensate ImmunoGen, all as set forth in this
      Agreement. 

    

    AGREEMENT

    

    In
      consideration of the mutual promises and covenants hereinafter set forth herein,
      and other consideration, the Parties agree as follows:

    

    1.
       Defined
      Terms. The
      following capitalized terms used in this Agreement have the meanings indicated
      below: 

     

    1.1  “Conjugation
      Process”
means
      a
      commercial-scale and commercial-grade process for manufacturing HER2 ADC by
      conjugating its component parts, which is to be developed under this Agreement.
      

     

    1.2  “Dedicated
      Equipment”
means
      the capital
      equipment identified on the Project Document as “Dedicated
      Equipment”.

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    1.3  “Genentech
      Materials”
means
      (i) a proprietary Genentech anti-HER2 antibody identified on the Project
      Document, and (ii) any other items identified on the Project Document as
“Genentech Materials” or delivered by Genentech under Section 2.6.
      

     

    1.4  “HER2
      ADC”
means
      a
      pharmaceutical product consisting of the following, in the form of a conjugate:
      (i) a proprietary Genentech anti-HER2 antibody referred to as trastuzumab,
      (ii[***] [***] (a linker moiety referred to as [***]), and (iii) a cytotoxic
      maytansinoid compound referred to as DM1.

     

    1.5  “Project
      Document”
means
      the attachments or appendices to this Agreement, which describe the Services,
      set forth the Requirements, and include other information, terms and conditions
      relevant to performance of the Services, as those attachments or appendices
      may
      be amended and updated under Section 2.1.
      

     

    1.6  “Project
      Materials”
means
      any materials - other than Genentech Materials - used for manufacturing an
      HER2
      ADC and otherwise performing the Services, including SMCC and DM1. 

     

    1.7  “Requirements”
means
      any specifications or requirements for any of the following: the Dedicated
      Equipment, the Genentech Materials, the Project Materials, the Services, or
      the
      Conjugation Process. 

     

    1.8  “Services”
means
      the process development work to be performed by ImmunoGen under this Agreement,
      as further described on the Project Document, including delivery of the
      documents embodying the Conjugation Process. 

     

    2.  Services.

     

    2.1  Project
      Document.
      The
      Project Document is intended to describe the Services and any other relevant
      terms and conditions for performance of the Services under this Agreement.
      The
      Project Document attached to this Agreement as of the Effective Date is
      preliminary; the Parties shall work in good faith to update and expand that
      preliminary Project Document, consistent with the preliminary Project Document
      and the terms and conditions of this Agreement, so that a final Project Document
      is complete within [***] ([***]) days after the Effective Date. The preliminary
      Project Document is incorporated into and forms an integral part of this
      Agreement; updated or amended Project Documents will become part of this
      Agreement upon execution by both Parties. In the event of a conflict between
      the
      terms in the main body of this Agreement and any terms of the Project Document,
      the main body of this Agreement controls. 

     

    2.2  Performance
      of Services. 
      ImmunoGen shall
      use
      commercially reasonable efforts to perform the Services in accordance with
      this
      Agreement, the Project Document
      and the
      Requirements. Without limiting the foregoing, ImmunoGen shall (i) make
      available facilities, utilities, equipment and computerized systems that are
      adequate to perform the Services in accordance with the Project Document; and
      (ii) provide an adequate number of personnel to perform the Services, all
      of whom have appropriate education, training and experience to do so. At
      Genentech’s request, ImmunoGen shall provide [***] or [***] for [***] [***] to
      [***] the Services. ImmunoGen is responsible for procuring any and all Project
      Materials, for ensuring that such Project Materials are suitable for the
      intended purposes, and for inspecting, testing, as appropriate, storing and
      maintaining Project Materials. Other than payment of fees under Section 3.1
      and
      Section 3.2 and reimbursement of certain out-of-pocket costs under Section
      3.3,
      ImmunoGen is responsible for all costs and expenses incurred in providing the
      Services. 

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    2.3  Schedule
      and Adjustments.
      ImmunoGen shall use commercially reasonable efforts to perform the Services
      on
      the schedule set forth in Section 3.2 and the Project Document, including timely
      completion of milestones. The schedule and milestones are material to Genentech,
      as is meeting the Requirements for the Conjugation Process. If there are any
      proposed changes to ImmunoGen’s personnel, facilities, utilities or equipment
      that are reasonably likely to affect the quality or timing of its performance
      of
      the Services, ImmunoGen shall promptly notify Genentech in writing of such
      proposed changes. If Genentech reasonably determines that any such proposed
      changes are likely to materially affect its development and/or commercialization
      of the HER2 ADC, the implementation of those changes will be subject to
      Genentech’s approval. If any delay in completing the Services is due to
      Genentech’s failure to perform its obligations under this Agreement, including
      but not limited to delay in providing Genentech Materials under
      Section 2.6,
      then
      the schedule (including the milestones in Section 3.2) will be adjusted
      accordingly to reasonably account for Genentech’s delay, after discussion and
      mutual agreement of the Parties. The schedule also will be adjusted to account
      for any delay caused by unavoidable delay in obtaining the [***] [***] [***]
      [***] to perform the Services; ImmunoGen shall use all reasonable efforts to
      avoid that delay and to mitigate the effect of that delay on meeting the
      schedule. 

     

    2.4  Project
      Management and Genentech Assistance.
      Each
      Party shall appoint designees to coordinate activities as appropriate. Those
      designees will meet on a weekly basis (more or less frequently if mutually
      agreed) to assess the progress of the Services. Decisions by those designees
      are
      not binding except to the extent consistent with the Project Document or agreed
      in writing by the Parties. Genentech shall provide ImmunoGen with guidance,
      information and assistance as reasonably necessary for ImmunoGen to perform
      the
      Services, and shall use reasonable efforts to perform any obligations under
      any
      Project Document related to such guidance and assistance. 

     

    2.5  Modifications
      of Services, Requirements or Project Document.
      If
      Genentech reasonably determines that modifications to the Services or any
      Requirements are necessary, Genentech shall communicate those modifications
      in
      writing to ImmunoGen. If ImmunoGen believes that any requested modifications
      are
      a material change to the Services or the Requirements, then ImmunoGen shall
      so
      inform Genentech, and shall include (i) an estimate of the length of any delay
      in the schedule, and/or (ii) an estimate of any revisions to the fees or costs.
      In any event, (a) ImmunoGen shall use commercially reasonable efforts to assist
      Genentech in implementing such modifications, (b) the Parties shall update
      the
      schedule in the Project Document (including the milestones), and (c) the Parties
      shall mutually agree on the fees and/or costs required to implement those
      modifications. Genentech shall be responsible for payment of all such agreed
      fees and/or costs, as reflected in the updated schedule in accordance with
      this
      Agreement. 

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    2.6  Genentech
      Materials.

     

    (a)  Procurement:
      Genentech shall deliver to ImmunoGen, at its own expense, the Genentech
      Materials in the form and amounts identified on the Project Document, unless
      the
      Project Document states that ImmunoGen is responsible for procurement. For
      any
      Genentech Materials to be procured by ImmunoGen, ImmunoGen shall procure those
      Genentech Materials in the form and in amounts identified on the Project
      Document and Genentech shall reimburse ImmunoGen
      under Section 3.3 or as set forth in the Project Document. Regardless of the
      Party responsible for procurement, ImmunoGen shall inspect the Genentech
      Materials (including by performing standard assays and other assays reasonably
      requested by Genentech in writing) to determine whether Genentech Materials
      comply with the applicable Requirements (or the written description of those
      Genentech Materials if no Requirements are stated), and shall inform Genentech
      of the results of that inspection. Genentech reserves the right to perform
      its
      own inspection or testing of the Genentech Materials. In either case, if
      Genentech determines that the Genentech Materials are not conforming,
      then:

     

    (1)  If
      procurement is ImmunoGen’s responsibility, then as ImmunoGen’s entire liability
      and Genentech’s sole remedy for provision of non-conforming Genentech Materials,
      ImmunoGen shall procure replacement Genentech Materials, subject to the same
      cost reimbursement as in the Project Document; or 

     

    (2)  If
      procurement is Genentech’s responsibility, then as Genentech’s entire liability
      and ImmunoGen’s sole remedy for provision of non-conforming Genentech Materials,
      (i) Genentech shall provide new or replacement Genentech Materials or, if that
      is not possible, then suggest an alternative and pay any additional costs for
      ImmunoGen to procure the alternative, and (ii) the Parties shall, as soon as
      practicable, agree to an adjusted schedule as necessary to account for any
      delay
      caused by non-conforming Genentech Materials. 

     

    (b)  Handling
      of Genentech Materials:
      ImmunoGen shall handle Genentech Materials in accordance with the following:
      (i) any labeling or documentation included with those Genentech Materials,
      (ii) any written instructions provided by Genentech, and
      (iii) reasonable handling procedures comparable to those ImmunoGen employs
      for similar materials. ImmunoGen may use Genentech Materials only for the
      Services and in accordance with any other restrictions set forth in the relevant
      Project Document. ImmunoGen may not transfer Genentech Materials to any third
      parties, including authorized subcontractors, unless it first obtains written
      permission from Genentech. ImmunoGen shall not chemically or biologically modify
      the Genentech Materials or use the Genentech Materials in connection with the
      development of any derivatives of the Genentech Materials, except as
      contemplated in the Project Document or except to the extent ImmunoGen receives
      written permission from Genentech. Any information describing or characterizing
      the Genentech Materials is Genentech’s Confidential Information. 

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    2.7  Dedicated
      Equipment. 

     

    (a)  Selection
      and Procurement:
      ImmunoGen
      shall select and procure the Dedicated Equipment. ImmunoGen shall use
      commercially reasonable efforts to ensure that the Dedicated Equipment conforms
      to the applicable Requirements, will work in its facility and is otherwise
      suitable for the intended purposes. 

     

    (b)  Use
      of Dedicated Equipment:
      ImmunoGen may use the Dedicated Equipment only for performing its obligations
      under this Agreement. ImmunoGen shall use the Dedicated Equipment only in
      accordance with any written instructions prescribed by Genentech or the
      manufacturer of the Dedicated Equipment, and shall perform such routine
      maintenance for the Dedicated Equipment as is required by such written
      instructions at no additional charge to Genentech. Except
      in
      connection with such routine maintenance or as directed in writing by Genentech,
      ImmunoGen shall not make any alterations, additions or improvements to
      the Dedicated
      Equipment. All alterations, additions or improvements so approved will be at
      Genentech’s sole cost and expense and will be the property of
      Genentech.

     

    (c)  Ownership
      and Risk of Loss; Disposition of Equipment:
      Genentech owns and shall continue to own all right, title and interest in and
      to
      any Dedicated Equipment. ImmunoGen assumes any risk of loss, damage, theft
      or
      destruction of the Dedicated Equipment while that Dedicated Equipment is in
      ImmunoGen’s possession or on ImmunoGen’s premises. Dedicated Equipment returned
      to Genentech must be returned in its original condition, reasonable wear and
      tear excepted. ImmunoGen shall [***] for all [***] to Dedicated Equipment that
      is [***] by ImmunoGen’s [***] or [***]. Upon termination or expiration of this
      Agreement, Genentech
      shall
      have the right to reclaim possession of such Dedicated Equipment at its expense
      upon reasonable notice and ImmunoGen shall reasonably cooperate with Genentech
      to
      return
      such Dedicated Equipment to Genentech in accordance with Genentech’s
      instructions. 

     

    3.  Compensation.
      

     

    3.1  Services
      Fees; Excluded Items.
      

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    (a)  Services
      Fees.
      Genentech
      shall pay to ImmunoGen fees, based on hours worked by ImmunoGen employees
      performing the Services, at a rate of $[***] per hour (the “Services Fees”).
      ImmunoGen shall [***] and [***] the [***] [***] based on [***] [***] [***]
      using
      an [***] [***] [***] and [***] of [***] in a [***] [***] by the [***] of [***]
      [***] to the Services. 

     

    (b)  Maximum
      Amounts.
      Genentech has no obligation to pay ImmunoGen for Services Fees that, in any
      given month, exceed the estimated cumulative Services Fees up to and including
      that month by more than [***] percent ([***]%), unless the Parties have agreed,
      in writing, to increase the Services Fees and that increase was agreed prior
      to
      Services Fees being incurred. Estimated Services Fees will be set forth in
      the
      Project Document (Exhibit A), and ImmunoGen shall notify Genentech promptly
      in
      the event that ImmunoGen reasonably estimates that the estimated Services Fees
      incurred by it through a given month will exceed those cumulative estimates.
        

     

    (c)  Excluded
      Items.
      Consistent with Section 2.6, Section 2.7, and Section 3.3, the
      transfer price for DM1 and the cost of Dedicated Equipment purchased by
      ImmunoGen are not included in the Services Fees described in this Section
      3.1.

     

    3.2  Milestone-Based
      Fees.
      Genentech shall pay ImmunoGen milestone-based fees upon mutual agreement that
      the associated milestones have been met within the time indicated.
      Milestones and associated milestone fees are set forth in the table below,
      although the schedule underlying the milestones may be adjusted as described
      in
      Section 2.5. The Parties acknowledge and agree that (a) each such milestone
      payment is not contingent upon completion of any other subsequent milestone
      or
      deliverable, and (b) if ImmunoGen fails to achieve a milestone and such failure
      is attributable to a delay caused by Genentech, all milestone dates that occur
      on and after the date of such delay shall be extended as described in Section
      2.3. ImmunoGen shall provide Genentech with prompt written notice upon its
      achievement of each of the milestones set forth in this Section 3.2. In the
      event that Genentech reasonably disagrees with the achievement of any such
      milestone, it shall so notify ImmunoGen in writing within [***] ([***]) days.
      Within [***] ([***])
      business days of any such notice by Genentech, the Parties shall use reasonable
      efforts to resolve the dispute. Any dispute that is not resolved within such
      [***] ([***]) business day period shall be submitted for resolution under
      Section 9.6.

     

    
      	
              Milestone
                Activity

            	
              Deliverables

            	
              Timing
                (T=Effective Date)*

            	
              Payment

            
	
              [***]
                [***]

            	
              Per
                Project Document

            	
              [***]:
                

              T+[***]
                [***]: 

              T+[***]

            	
              [***]$[***]
                if the [***] [***] is [***], and $[***] [***] [***] if the [***]
                [***] is
                [***]

            
	
              [***]
                of [***] [***]

            	
              Per
                Project Document

            	
              [***]:
                T+[***] [***]

               

            	
              $150,000
                if the[***]is [***]

            
	
              [***]
                [***]/

              [***]

            	
              Per
                Project Document

            	
              [***]:
                T+[***]: T+[***]

            	
              $[***]
                if the [***] [***] is [***]and [***]$[***] [***]if the [***]is
                [***]

            
	
              [***]
                [***]

            	
              Per
                Project Document

            	
              Per
                Project Document

            	
              $[***]

            

    

    

    *The
      exact timing for each milestone is subject to the preparation of the final
      Project Document; however, the Project Document must reflect the relative timing
      (i.e.,
      the amount of time from “T”) in the above table. 

    

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    3.3  Cost
      Reimbursement.
      Genentech shall reimburse ImmunoGen for any DM1 consumed in performance of
      the
      Services based on [***] [***] cost of such DM1,[***]which will be included
      in
      the final Project Document, along with the amount expected to be consumed.
      Genentech has no obligation to reimburse ImmunoGen for amounts in excess of
      that
      expected amount unless mutually agreed in writing. Genentech also is responsible
      for the direct and actual cost of any Genentech Materials to be procured
      directly by ImmunoGen (if any) and for the Dedicated Equipment (including
      shipping), with those Genentech Materials and the method of compensating
      ImmunoGen to be set forth in the Project Document (whether providing the
      Dedicated Equipment directly to ImmunoGen, advancing ImmunoGen the amounts
      to
      purchase the Dedicated Equipment, or reimbursing ImmunoGen its actual
      out-of-pocket costs for the Dedicated Equipment).
      

     

    3.4  Invoices
      and Payment Terms.
      ImmunoGen
      shall generate invoices for all fees and cost reimbursements. Invoices for
      Services Fees and for cost reimbursements must be generated monthly and provided
      to Genentech promptly after the end of the month in which the fees were
      incurred; invoices for milestone-based fees may be generated any time after
      completion of the milestone (as completion is determined under the Project
      Document and Section 3.2). Invoices for cost reimbursement must include
      appropriate documentation of costs incurred; invoices for Services Fees must
      detail the [***] [***] Services and the number of hours spent in performing
      Services, as calculated in accordance with Section 3.1, during the month for
      which the invoice applies; and invoices for milestone-based fees must identify
      the milestone completed. Genentech shall pay [***] invoices within [***] ([***])
      days after receipt of each invoice or a facsimile
      copy of each invoice. Receipt or acceptance by Genentech of any invoices under
      this Agreement does not and will not preclude Genentech from questioning the
      correctness of the underlying information at a later date, or from exercising
      its rights under Section 3.5. If any [***] inconsistencies or mistakes are
      discovered in an invoice, the Parties shall make immediate adjustment, by
      reimbursement or credit, as applicable. Invoices
      that remain unpaid more than [***] ([***]) days beyond the scheduled payment
      due
      date may be subject to an interest charge equal to one percent (1%) per month
      (twelve percent (12%) per annum), calculated from the scheduled payment due
      date
      forward; provided that in no event shall such annual rate exceed the maximum
      interest rate permitted by law in regard to such payments. Such payments when
      made shall be accompanied by all interest so accrued. All payments shall be
      made
      by wire transfer of immediately available funds to the following
      account:

     

    [***]

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    ABA
      (routing): [***]

    F/C
      Client Funds # [***]

    Account:
      [***]

    Account
      Title: ImmunoGen, Inc.

    

    3.5  Records
      Maintenance.
      ImmunoGen
      shall maintain all records and accounts pertaining to the Services under this
      Agreement for a period of at least [***] ([***]) years from the date of final
      payment for the Services, or longer if required by law. At the request of
      Genentech, upon at least [***] ([***]) business days’ prior written notice, but
      no more often than once per calendar year, and at its sole expense, ImmunoGen
      shall permit an independent certified public accountant selected by Genentech
      and reasonably acceptable to ImmunoGen to inspect (during regular business
      hours) the relevant records required to be maintained by ImmunoGen under this
      Section 3.5. To the extent requested by ImmunoGen, the accountant shall enter
      into a confidentiality agreement with both Parties reasonably acceptable to
      each.  The
      results of any such audit shall be made available to both Parties. Genentech
      agrees to treat the results of any such accountant’s review of ImmunoGen’s
      records under this Section 3.5 as Confidential Information of ImmunoGen subject
      to the terms of Section 5.

     

    3.6  Sole
      Compensation.
      Genentech has no obligation to pay any amounts not specified in this Agreement
      (including the Project Document). The fees and costs under Section 3.1, Section
      3.2 and Section 3.3 are inclusive of all costs associated with the Services,
      including time, materials, and indirect and direct overhead (where applicable
      and authorized to be included in the invoiced amount). The milestone-based
      fees
      in Section 3.2 are payable only if the milestones are achieved by ImmunoGen
      as
      described in the Project Document, are within the dates indicated (as such
      dates
      may be adjusted per Section 2.5), and are accepted by Genentech as described
      in
      Section 3.2, all regardless of the level of effort expended by ImmunoGen.

     

    4.  Inventions.
      

     

    4.1  Definitions.
      For
      purposes of this Agreement, the following capitalized terms have the meanings
      set forth below: 

     

    (a)  Project
      Inventions: “Project
      Inventions”
are
      inventions, original works of authorship, developments, concepts, know-how,
      improvements or trade secrets, whether or not patentable,
      arising out ImmunoGen’s activities in connection with its performance of the
      Services.

     

    (b)  Project
      Patents: “Project
      Patents”
are
      rights in and to U.S. and ex-U.S. patents and patent applications and any
      patents issuing therefrom, and in and to any reissues, extensions,
      registrations, continuations, divisions, continuations-in-part, reexaminations,
      substitutions or renewals thereof, and supplementary protection certificates
      based on any of the foregoing, all to the extent having a priority date after
      the Effective Date and claiming Project Inventions.

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    (c)  ImmunoGen
      Field: “ImmunoGen
      Field”
has
      the
      definition set forth in the (amended) License Agreement which for convenience
      is
      as follows:

     

    “ImmunoGen
      Field” means any and all uses other
      than
      any use
      that involves an antibody that binds to an antigen that is subject to an
      exclusive license from ImmunoGen under, or arising from, the Heads of Agreement
      or an antigen that is subject to an Exclusive Target Option under the Heads
      of
      Agreement, during the period that such exclusive license or Exclusive Target
      Option remains in effect.

    

    4.2  Disclosure.
      ImmunoGen shall disclose to Genentech, promptly (but no later than upon each
      milestone or upon completion of a phase) any and all Project Inventions.

     

    4.3  Project
      Inventions and Project Patents.
      All
      Project Inventions, and any Project Patents, will be jointly owned by Genentech
      and ImmunoGen. As such, each Party shall retain an undivided one-half interest
      in and to those Project Inventions and Project Patents, and each Party is free
      to exploit any Project Invention or Project Patent in any field and for any
      purpose, without the consent of and without any duty of payment or accounting
      to
      the other Party, subject to the following limits and exceptions:
      (i) ImmunoGen’s use and exploitation of Project Inventions and Project
      Patents is limited to the ImmunoGen Field; and (ii) Genentech may grant
      licenses of Project Patents and Project Inventions to third parties only in
      connection with: (A) the grant of a license to research, develop, manufacture
      or
      commercialize any products researched, developed, manufactured or commercialized
      by Genentech; (B) the grant of a license to a portfolio of rights controlled
      by
      Genentech (which, for purposes of clarity shall not include any license grant
      that covers only the Project Patents or Project Inventions); or (C) solely
      for the purpose of performing services for Genentech. Where the laws of any
      jurisdiction would grant one Party a right to require payment, accounting or
      consent not consistent with the above, that Party hereby waives any such right.
      Each Party shall execute, acknowledge and deliver further instruments, and
      undertake other acts, as reasonably necessary and appropriate to implement
      any
      of the foregoing. 

     

    4.4  Relationship
      to License Agreement.
      It is
      understood that to the extent that Project Inventions and/or Project Patents
      are
      covered by the definitions of “Licensed Patent Rights” or “Licensed Technology”
under the License Agreement, such Project Inventions and Project Patents shall
      be included as part of the licenses granted under the License Agreement. This
      Agreement is not intended to, and the terms of this Agreement will not be deemed
      to, modify or amend any licenses, terms or definitions in the License Agreement.
      

     

    4.5  Patent
      Prosecution, Maintenance and Enforcement.
      Drafting, prosecution, defense and maintenance of the Project Patents will
      be
      handled by outside counsel reasonably acceptable to both Parties. The outside
      counsel will be instructed to provide copies of all material prosecution
      documents and correspondence with all patent offices to both ImmunoGen and
      Genentech, to incorporate to the extent reasonably possible suggestions from
      both ImmunoGen and Genentech, and to inform each Party of contradictory or
      potentially contradictory positions. If Genentech and ImmunoGen are unable
      to
      reconcile those positions, then [***] will make the final determination. Costs
      of drafting, prosecution, defense and maintenance will be shared equally.
      Neither Party may enforce a Project Patent without the consent of the other
      Party which consent shall not be unreasonably withheld or delayed; costs and
      proceeds of enforcement will be determined by mutual agreement, but consistent
      with the relative value each Party receives from those Project Patents in the
      marketplace. In any event, to the extent doing so would not prejudice or limit
      a
      right or privilege either Party may have, the Parties will consult with each
      other in good faith regarding the best manner in which to proceed in connection
      with any actual, alleged or threatened infringement of any Project Patents,
      including actions against any alleged infringer.

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    5.  Confidential
      Information. 

     

    5.1  Definition.
      For
      purposes of this Agreement, “Confidential
      Information”
      means:

     

    (a)  with
      respect to both Parties, the terms and conditions of this Agreement (including
      the Project Document); and 

     

    (b)  with
      respect to Genentech, (i) any proprietary or non-public descriptions or
      characterizations of the Genentech Materials or of the HER2 ADC, and (ii) any
      and all information related to any clinical program, any development
      determinations, any research information, and any other information related
      to
      any Genentech Materials, Genentech’s anti-HER2 antibody program, the HER2 ADC,
      and any other antibody-drug conjugates on which Genentech is working and (iii)
      the Conjugation Process and any nonpublic descriptions or other non-public
      and
      proprietary information about the Conjugation Process (“Conjugation Process
      Confidential Information”); and 

     

    (c)  with
      respect to ImmunoGen, (i) any proprietary or non-public information in relation
      to DM1, other maytansinoid compounds or any conjugation processes other than
      the
      Conjugation Process (“Process-Related Confidential Information”), and (ii) any
      scientific, technical or financial information of ImmunoGen disclosed through
      an
      audit report prepared pursuant to this Agreement. 

     

    (d)  None
      of
      the foregoing (a), (b), or (c) will be considered Confidential Information
      if:
      (i) as of the date of disclosure, it is known to the receiving Party or its
      Affiliates, as
      demonstrated by credible written documentation, other than by virtue of a prior
      confidential disclosure to such receiving Party or its Affiliates; (ii) as
      of
      the date of disclosure it is in the public domain, or it subsequently enters
      the
      public domain through no fault of the receiving Party or its Affiliates; (iii)
      it is obtained by the receiving Party from a Third Party having a lawful right
      to make disclosure free from any obligation of confidentiality to the disclosing
      Party; or (iv) it is independently developed by or for the receiving Party
      without reference to or use of any Confidential Information of the disclosing
      Party as demonstrated by credible written documentation.

     

    5.2  Obligations
      of Non-Disclosure and Non-Use.
      During
      the term of this Agreement and for a period of [***] ([***]) years after
      expiration or earlier termination of this Agreement, a Party receiving
      Confidential Information of the other Party shall, except to the extent
      authorized under Section 5.3 or in writing by the disclosing Party:
      (i) hold such Confidential Information in strict trust and confidence and
      not disclose such Confidential Information to any Third Party without prior
      written consent of the other Party; and (ii) not use such other Party’s
      Confidential Information for any purpose except those permitted by this
      Agreement. Genentech shall have the right to use for internal research and
      development purposes any Process-Related Confidential Information but shall
      only
      have the right to disclose such Process-Related Confidential Information to
      Third Parties pursuant to Section 5.3 and (b) ImmunoGen shall have the
      right to use for internal research and development purposes, in the ImmunoGen
      Field, any Conjugation Process Confidential Information. 

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    5.3  Authorized
      Disclosure and Use of Confidential Information.
      

     

    (a)  Terms
      of this Agreement:
      Although the terms of this Agreement are the Confidential
      Information of both Parties and subject to Section 5.2, such terms may be
      disclosed to potential collaborators and licensees (including potential
      co-marketing and co-promotion contractors), research collaborators, employees,
      third party contractors, and consultants whose tasks are related to performance
      of this Agreement and to
      attorneys and accountants retained to represent a Party in connection with
      transactions related to this Agreement,
      each of
      whom prior to disclosure are bound by similar obligations of confidentiality
      and
      non-use at least equivalent in scope to those set forth in this Article;
      provided that the Party disclosing such information to any of the above other
      than its employees,
      attorneys and accountants
      shall
      use reasonable efforts to obtain the prior written consent of the Party whose
      information is being disclosed, which consent may be conditioned upon redacting
      certain terms prior to disclosure. 

     

    (b)  Authorized
      Disclosure and Use of Confidential Information:
      Each
      receiving Party may disclose the other Party’s Confidential Information to the
      extent such disclosure is reasonably necessary in the following instances,
      and
      after providing notice of such disclosure to the disclosing Party: (i) filing
      or
      prosecuting Project Patents in accordance with Article 4; (ii) regulatory
      filings related to the HER2 ADC; (iii) prosecuting or defending litigation,
      provided that the disclosing Party must seek and use reasonable efforts to
      obtain a protective order or other appropriate confidential treatment; or
      (iv) where Genentech is the receiving Party, and where Genentech is
      developing, distributing, marketing or commercializing a product, Genentech
      may
      disclose Process-Related Confidential Information in connection with
      commercialization of those products, including to sublicensees, potential
      sublicensees, and contract manufacturers that are subject to obligations of
      confidentiality comparable to Genentech’s
      obligations set forth in this Article 5. Further,
      each receiving Party may use and disclose the other Party’s Confidential
      Information, when Confidential Information constitutes intellectual property
      licensed to a Party under this Agreement, to the extent of the license
      granted.

     

    5.4  Press
      Releases.
      Neither
      ImmunoGen nor Genentech shall issue any press release or make any other public
      announcement concerning the existence of this Agreement, the relationship
      between the Parties, the subject matter of this Agreement, the scope or subject
      of the Services, or the results or success of the Services (“Public
      Release”),
      except: (i) to the extent permitted by prior consent of the other Party;
      (ii) to the extent required by law or by the requirements of the Securities
      and Exchange Commission or the national securities exchange, quotation system
      or
      over-the-counter stock market on which such Party’s securities are traded
      (together, the “Exchange”),
      but
      only after approval, which will not be unreasonably withheld; and (iii) a
      one-time press release, after the execution of this Agreement, in the form
      of
      Exhibit B to this Agreement. Requests for consent to any Public Release
      (including (i) and (ii) above must be submitted to the other Party no less
      than
      [***] ([***]) business days prior to the proposed date of such Public Release;
      provided
      that
      each Party’s approval may be delayed until the occurrence of the event
      triggering such Public Release. If the Parties agree that a disclosure or filing
      needs to be made more quickly, then the reviewing Party shall use reasonable
      efforts to provide review more quickly. Proposed filings with an Exchange must
      be submitted no less than [***] ([***]) business days prior to the date of
      the
      proposed filing; however, if the Parties agree that a disclosure or filing
      needs
      to be made more quickly, then the reviewing Party shall use reasonable efforts
      to provide review more quickly. When information is required to be filed with
      an
      Exchange, the filing Party shall redact the Confidential Information of the
      other Party to the extent its disclosure is not legally required, and shall
      seek
      confidential treatment of the Agreement if filed as an Exhibit. Each Party
      shall
      obtain its own legal advice regarding compliance with securities laws and,
      upon
      request of the non-disclosing Party, shall provide evidence of the necessity
      of
      such disclosure, by means of an opinion of counsel or similar
      document.

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    6.  Representations,
      Warranties, and Disclaimers.
      

     

    6.1  By
      ImmunoGen.
      ImmunoGen represents and warrants that its performance of the Services does
      and
      will continue to comply with all applicable federal, state and local laws,
      requirements and regulations. ImmunoGen further represents and warrants that,
      to
      the best of its knowledge, the Conjugation Process and any documents delivered
      by ImmunoGen under this Agreement in connection with delivery of the Conjugation
      Process, do not, and will not, infringe a third party’s intellectual property
      rights, except to the extent ImmunoGen so informs Genentech prior to developing
      that Conjugation Process.

     

    6.2  No
      Conflict.
      Each
      Party represents and warrants that the execution of this Agreement, and its
      performance of the Agreement does not and will not conflict with any agreement,
      instrument or understanding, oral or written, to which it is a party or by
      which
      it is bound, nor violate any law or regulation of any court, governmental body
      or administrative or other agency having jurisdiction over it. 

     

    6.3  Disclaimer
      of Warranties.
      EXCEPT
      AS OTHERWISE PROVIDED IN SECTION 6.1 AND 6.2, IMMUNOGEN DISCLAIMS ANY IMPLIED
      OR
      STATUTORY WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF
      MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE SERVICES PROVIDED
      HEREUNDER. The provisions of this Section will not be deemed to limit any
      obligations ImmunoGen has under the written terms of this Agreement.

     

    6.4  [***]
      of [***] [***].
      IN NO
      EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR
      ANY
      CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES
      (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED
      OR
      INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH THIS
      AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING
      DISCLAIMER AND EXCLUSION [***] [***] [***] TO THE [***] [***] [***] ARISE OUT
      OF
      [***] AND [***] [***] OF THE [***] TO [***] WITH [***] [***] OR FROM [***]
      AND
      [***] [***] OF THE [***] OF [***]. THE FOREGOING DISCLAIMER AND [***] WILL
      [***]
      BE [***] TO [***] OR [***] ANY [***] [***] TO BE [***] TO A [***] [***] PURSUANT
      TO THE [***] PROVISIONS. 

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    6.5  Limitation
      of Liability.
      BOTH
      PARTIES HEREBY AGREE THAT TO THE FULLEST EXTENT PERMITTED BY LAW, EACH PARTY’S
      LIABILITY TO THE OTHER, FOR ANY AND ALL INJURIES, CLAIMS, LOSSES, EXPENSES,
      OR
      DAMAGES, WHATSOEVER, ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT
      FROM
      ANY CAUSE OR CAUSES, INCLUDING, BUT NOT LIMITED TO, NEGLIGENCE, ERRORS,
      OMISSIONS OR STRICT LIABILITY, SHALL NOT EXCEED UNDER THIS AGREEMENT AN AMOUNT
      EQUAL TO [***] [***] DOLLARS ($[***]), OR, IF GREATER, THE AGGREGATE
      CONSIDERATION PAID BY GENENTECH TO IMMUNOGEN UNDER THIS AGREEMENT. [***] FOR
      THE
      [***] AND [***] [***] OF [***] OF [***], AND AMOUNTS PAID TO THIRD PARTIES
      PURSUANT TO THE INDEMNIFICATION PROVISIONS, ARE NOT SUBJECT TO THE LIMITATIONS
      IN THIS SECTION. TO THE EXTENT THAT THIS CLAUSE CONFLICTS WITH ANY OTHER CLAUSE,
      THIS CLAUSE SHALL TAKE PRECEDENCE OVER SUCH CONFLICTING CLAUSE. IF APPLICABLE
      LAW PREVENTS ENFORCEMENT OF THIS CLAUSE, THEN THIS CLAUSE SHALL BE DEEMED
      MODIFIED TO PROVIDE THE MAXIMUM PROTECTION FOR THE PARTY FROM WHICH DAMAGES
      ARE
      BEING SOUGHT AS IS ALLOWABLE UNDER APPLICABLE LAW.

     

    7.  Term
      and Termination.
      

     

    7.1  Term.
      This
      Agreement commences on the Effective Date and, unless earlier terminated,
      continues until either completion of the Services or, if the Services are not
      completed, then three (3) years after the Effective Date. 

     

    7.2  Termination.
      Subject
      to Section 7.3 (Obligations Upon Termination or Expiration), this Agreement
      may
      be terminated, or any particular Services under this Agreement may be
      terminated: (i) automatically upon expiration of the License Agreement;
      (ii) subject to the termination fees in Section 7.3 below, (a) by
      Genentech, at any time, and for any reason or no reason,
      by providing written notice of termination to ImmunoGen at least [***] ([***])
      days prior to the date of termination, which notice specifies the scope of
      the
      terminated activities, whether all or a part of the Services; and (b) by
      Genentech, upon written notice after a Change of Control of ImmunoGen (as
“Change of Control” is defined in Section 9.1);
      and
      (iii) by either Party, by providing written notice of termination to the
      other Party at least [***] ([***]) days after having provided to the other
      Party
      notice of such Party’s material breach of this Agreement, unless such material
      breach has been cured within the [***] ([***]) day period after the initial
      notice of breach; provided, however, that when a Party allegedly in breach
      disputes in good faith that a breach has occurred, then both Parties shall
      continue performance during the pendency of any dispute resolution procedure
      for
      up to a maximum of [***] ([***]) months after notice of an alleged material
      breach. 

     

    7.3  Obligations
      Upon Termination or Expiration.
      

     

    (a)  Payment
      by Genentech:
      Upon
      termination or expiration of this Agreement, Genentech shall pay ImmunoGen:
      (i) Services Fees under Section 3.1 that were authorized to be incurred and
      were actually incurred prior to termination; (ii) reimbursable costs not
      already paid, to the extent such costs already have been incurred (subject
      to
      return of the Dedicated Equipment as specified herein); and (iii) any early
      termination fee as calculated under subsection (b) below. 

     

    (b)  Early
      Termination [***]:
      If
      Genentech terminates this Agreement under Section 7.2 (ii) above for its
      convenience prior to [***] after initiation of the Services (i.e.,
      T
      + [***]
      in the chart in Section 3.2),
      then
      Genentech shall [***] if that termination occurs prior to [***] after initiation
      of the Services or (ii) [***] if that termination occurs between [***] and
      [***] after initiation of the Services. If ImmunoGen has achieved the milestones
      for the Services, and if Genentech had paid ImmunoGen the associated milestone
      fees, then the foregoing [***] of the milestone-based fees [***]; provided
      that in
      the above circumstance the [***] if Genentech terminates for its convenience
      prior to [***] after initiation of the Services and at least [***] if Genentech
      terminates for its convenience prior to [***] after initiation of the Services.
      

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    (c)  Assistance
      and Works in Progress:
      At
      Genentech’s request at any time prior to termination or expiration or within
      [***] ([***]) days after termination or expiration of this Agreement, ImmunoGen
      shall: (i) provide to Genentech reasonable assistance with transition of
      the Services to Genentech or to a third party selected by Genentech, subject
      to
      payment of ImmunoGen’s direct costs for such assistance; (ii) deliver to
      Genentech copies of all works in progress for any documentation or other items
      to be delivered as part of the Services, whether or not the underlying Services
      had been completed prior to termination; (iii) for up to [***] ([***])
      months after delivery of the items in clause (ii), respond to inquiries
      from Genentech regarding such works in progress or documentation; and (iv)
      arrange for the return of any Dedicated Equipment required under
      Section 2.7.
      

     

    7.4  Survival.
      The
      following Articles and Sections survive any termination or expiration of this
      Agreement: Section 1 (Defined Terms), 2.6
      (Genentech Materials), Article 3 (Compensation) (to the extent the obligation
      arose prior to the end of the term), Article 4 (Inventions), Article 5
      (Confidential Information) (for the period indicated), Article 6
      (Representations, Warranties and Disclaimers), Section 7.3 (Obligations Upon
      Termination or Expiration),
      Article 8 (Indemnity and Insurance) (for the period indicated), and Article
      9
      (Miscellaneous).

     

    8.  Indemnity
      and Insurance.
      

     

    8.1  Indemnification
      by ImmunoGen.
      Subject
      to Section 8.3 below and the remainder of this Section 8.1, ImmunoGen shall
      indemnify, defend and hold harmless Genentech, its Affiliates and their
      respective directors, officers, employees, and agents and their respective
      successors, heirs and assigns (the “Indemnitees”),
      from
      and against any liability, damage, loss or expense (including reasonable
      attorney’s fees and expenses of litigation) incurred by or imposed upon such
      Indemnitees, or any of them, in connection with any third party claims, suits,
      actions, demands or judgments, including without limitation, personal injury
      and
      product liability matters that arise out of or relate to (i) the material breach
      of this Agreement by ImmunoGen, (ii) the negligence or willful misconduct
      on the part of ImmunoGen, and (iii) ImmunoGen’s failure to comply with
      applicable laws. 

     

    8.2  Indemnification
      by Genentech.
      Subject
      to Section 8.3 below and the remainder of this Section 8.2, Genentech shall
      indemnify, defend and hold harmless ImmunoGen, its Affiliates and their
      respective directors, officers, employees, and agents and their respective
      successors, heirs and assigns (the “Indemnitees”),
      from
      and against any liability, damage, loss or expense (including reasonable
      attorney’s fees and expenses of litigation) incurred by or imposed upon such
      Indemnitees, or any of them, in connection with any third party claims, suits,
      actions, demands or judgments, including without limitation, personal injury
      and
      product liability matters (but excluding any patent, trademark or tradename
      infringement matters, which are governed by the License Agreement), that arise
      out of or relate to (i) any actions or omissions of Genentech or of its
      sublicensee in the development, testing, production, manufacture, supply,
      promotion, import, sale or use by any person of any product that is manufactured
      using the Conjugation Process provided under this Agreement, which product
      is
      manufactured or sold by Genentech or any of its sublicensees, (ii) the material
      breach of this Agreement by Genentech, or (ii) the negligence or willful
      misconduct on the part of Genentech, in any such case under this Section 8.2,
      except to the extent of ImmunoGen’s responsibility therefore under Section 8.1
      above. 

     

    8.3  Indemnification
      Procedures.
      As a
      condition of obtaining indemnification under Section 8.1 or Section 8.2 above
      (as applicable), the Party seeking indemnification shall (i) promptly
      inform the indemnifying Party, in writing, of the third party claim for which
      it
      will be seeking indemnification, (ii) provide to the indemnifying Party all
      right and authority to defend or settle that third party claim, and
      (iii) provide all necessary assistance in such defense or settlement. An
      indemnifying Party has no indemnity obligation if the indemnified Party has
      settled or compromised a claim without its consent. An indemnifying Party shall
      not settle or compromise a claim by admitting fault of the indemnified Party,
      or
      entering into a settlement in which the indemnified Party has any obligation
      other than the payment of money damages. If the indemnifying Party is defending
      a claim, the indemnified Party may participate, at its own expense and with
      its
      own counsel. 

     

    8.4  Insurance.
      Genentech and ImmunoGen each shall maintain insurance with respect to its
      activities hereunder. Such insurance shall be in such amounts and subject to
      such deductibles as the Parties may agree, based upon standards prevailing
      in
      the industry at the time. If
      the
      Parties do not agree, then the requirements below apply. Genentech may satisfy
      its obligations under this Section through self-insurance to the same
      extent.

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    (a)  Coverage
      Types: 

     

    (1)  Commercial
      General Liability:
      ImmunoGen shall maintain commercial general liability coverage (including
      contractual liability and personal advertising coverage) for limits no less
      than
      $[***] per occurrence and $[***] in the aggregate. The policy form will be
      an
“occurrence” form. If claims made, ImmunoGen shall maintain coverage including
      completed operations for a minimum of [***] ([***]) years following termination
      or completion of the Services. 

     

    (2)  Product
      Liability:
      ImmunoGen shall maintain product liability coverage for limits no less than
      $[***] per occurrence and $[***] in the aggregate.

     

    (3)  Workers’
      Compensation Coverage:
      ImmunoGen shall maintain statutory limits and Employer’s Liability for limits no
      less than $[***]. Coverage will include a waiver of subrogation endorsement
      in
      favor of Genentech where applicable by law. 

     

    (b)  OtherRequirements:
      

     

    (1)  Additional
      Insured:
      ImmunoGen shall name Genentech as an additional insured by endorsement.

     

    (2)  Occurrence
      Form:
      The
      insurance policies above will be under an occurrence form; however, if only
      a
      claims-made form is available, then in such a case, ImmunoGen shall maintain
      the
      claims-made insurance policy for at least [***] ([***]) years following
      completion of services under the Agreement.

     

    (3)  Financial
      Rating:
      The
      above insurance must be carried with insurance companies with an
      A.M. Best’s rating of A-VII or better.

     

    (4)  Certificate
      of Insurance:
      Upon
      [***] ([***]) days of executing this Agreement, ImmunoGen shall provide
      Genentech with its certificate of insurance evidencing the insurance coverage
      set forth in this section. ImmunoGen shall provide to Genentech at least [***]
      ([***]) days prior written notice of any cancellation, non-renewal or material
      change in any of such insurance coverage.

     

    

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    9.  Miscellaneous. 

     

    9.1  Subcontracting
      and Use of Contract Manufacturing Organizations.
      ImmunoGen shall not subcontract any of its obligations under this Agreement
      without Genentech’s prior written consent. Even under an authorized subcontract,
      ImmunoGen shall not provide Genentech Materials to a third party without
      Genentech’s written authorization. To the extent Genentech Materials are
      required for performance under an authorized subcontract, Genentech either
      shall
      provide the Genentech Materials directly to the authorized subcontractor, or
      shall authorize ImmunoGen to provide the Genentech Materials to the authorized
      subcontractor, in either case subject to an appropriate material transfer
      agreement or other agreement between Genentech and the authorized subcontractor.
      

     

    9.2  Assignment
      and Change of Control.
      Except
      to the extent authorized in writing by Genentech in advance, ImmunoGen shall
      not
      assign or otherwise transfer any right or obligations under this Agreement
      to a
      third party without Genentech’s prior written consent. Assignment without such
      consent is void and of no effect. However, if ImmunoGen is the subject of a
      Change of Control, then this Agreement will be deemed assigned and transferred
      in connection with that Change of Control. For purposes of this Agreement,
      a
“Change
      of Control”
is
      a
      transaction or a series of related transactions in which one or more affiliated
      parties that previously did not own at least a fifty percent (50%) interest
      in
      ImmunoGen obtains at least a fifty percent (50%) interest in ImmunoGen, or
      (ii)
      a third party acquires all or substantially all of ImmunoGen’s assets to which
      this Agreement relates. ImmunoGen shall provide to Genentech written notice
      of
      any Change of Control within [***] ([***]) business days after entering into
      an
      agreement for a Change of Control (or, if such Change of Control is not
      disclosed publicly, then at the same time as public disclosure). At any time
      within [***] ([***]) months after any Change of Control of ImmunoGen, Genentech
      may terminate this Agreement, subject to Section 7.3. Whether or not this
      Agreement is terminated, any permitted assignee shall assume all rights and
      obligations of its assignor under this Agreement.

     

    9.3  Severability
      and Invalidity.
      Each
      Party hereby agrees that it does not intend to violate any public policy,
      statutory or common laws, rules, regulations, treaty or decision of any
      government agency or executive body thereof of any country or community or
      association of countries. Should one or more provisions of this Agreement be
      or
      become invalid, the Parties hereto shall substitute, by mutual consent, valid
      provisions for such invalid provisions which valid provisions in their economic
      effect are sufficiently similar to the invalid provisions that it can be
      reasonably assumed that the Parties would have entered into this Agreement
      with
      such provisions. In case such provisions cannot be agreed upon, the invalidity
      of one or several provisions of this Agreement shall not affect the validity
      of
      this Agreement as a whole, unless the invalid provisions are of such essential
      importance to this Agreement that it is to be reasonably assumed that the
      Parties would not have entered into this Agreement without the invalid
      provisions.

     

    9.4  Notices.
      Any
      consent, notice or report required or permitted to be given or made under this
      Agreement by one of the Parties hereto to the other shall be in writing,
      delivered personally or by facsimile (and promptly confirmed by personal
      delivery, first class air mail or courier), first class air mail or courier,
      postage prepaid (where applicable), addressed to such other Party at its address
      indicated below, or to such other address as the addressee shall have last
      furnished in writing to the address or in accordance with this Section 9.4
      and
      (except as otherwise provided in this Agreement) shall be effective upon receipt
      by the addressee.

     

    If
      to
      ImmunoGen:

    ImmunoGen,
      Inc.

    128
      Sidney Street

    Cambridge,
      MA 02139

    Attention:Senior
      Vice President

          Corporate
      Development and
      Operations

    

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    With
      copy to:

    ImmunoGen,
      Inc.

    128
      Sidney Street

    Cambridge,
      MA 02139

    Attention:
      Chief Financial Officer

    

    

    If
      to
      Genentech:

    Genentech,
      Inc.

    1
      DNA
      Way

    South
      San
      Francisco, CA 94080

    Telephone:
      (650) 225-1000

    
      	 	 	
              Facsimile:
                (650) 467-9146

            

    

    
      	 	 	
              Attention:
                Corporate Secretary

            

    

    

    
      	 	 	
              With
                copy to: 

            

    

    Genentech,
      Inc.

    1
      DNA
      Way

    South
      San
      Francisco, CA 94080

    
      	 	 	
              Attention:
                Vice President, Manufacturing Collaborations

            

    

    

    9.5  Governing
      Law.
      The
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of California applicable to contracts entered into and to be performed
      entirely within the State of California.

     

    9.6  Dispute
      Resolution.
      The
      Parties shall attempt to resolve any dispute between them amicably and if a
      dispute should arise, either Party may, by written notice to the other Party,
      have such dispute referred to Genentech’s designated officer with settlement
      authority and ImmunoGen’s Chief Executive Officer for attempted resolution by
      good faith negotiations commencing promptly after such notice is received.
      If
      the senior officials are not able to resolve the dispute, then the Parties
      may
      seek to mediate that dispute, on terms and with a mediator mutually agreeable
      to
      the Parties. The Parties also may seek to arbitrate that Dispute, on mutually
      agreed terms and conditions. Neither Party is required or obligated to mediate
      or arbitrate. The dispute resolution provisions of this Section are in addition
      to any other relief and remedies available to either Party at law or in equity.
      

     

    9.7  Entire
      Agreement.
      The
      License Agreement, the Development Agreement, the Clinical Supply Agreement,
      the
      Heads of Agreement, the PD Heads of Agreement and the Quality Services Agreement
      remain in force, in accordance with their terms, with respect to the subject
      matter thereof. To the extent the terms and conditions of this Agreement
      necessarily would conflict with any of the terms and conditions of the License
      Agreement, the Development Agreement, the Clinical Supply Agreement, the Heads
      of Agreement, the PD Heads of Agreement and the Quality Services Agreement,
      the
      terms and conditions of this Agreement control, but only with respect to the
      Services that are the subject of this Agreement. Except for the foregoing
      agreements, this Agreement contains the entire understanding of the Parties
      with
      respect to the Services, and supersedes any prior agreements and understandings,
      either oral or written, related to the subject matter hereof. This Agreement
      may
      be amended, or any term hereof modified, only by a written instrument duly
      executed by both Parties hereto. 

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    9.8  Waiver.
      The
      terms or conditions of this Agreement may be waived only by a written instrument
      executed by a duly authorized representative of the Party waiving compliance.
      The failure of either party at any time or times to require performance of
      any
      provision hereof shall in no manner affect its rights at a later time to enforce
      the same. No waiver by either Party of any condition or term shall be deemed
      as
      a continuing waiver of such condition or term or of another condition or term.
      

     

    9.9  Independent
      Contractors.
      ImmunoGen and Genentech each acknowledge that they shall be independent
      contractors and that the relationship between the two Parties shall not
      constitute a partnership, joint venture, agency or any type of fiduciary
      relationship. Neither ImmunoGen nor Genentech shall have the authority to make
      any statements, representations or commitments of any kind, or to take any
      action, which shall be binding on the other Party, without the prior consent
      of
      the other Party to do so.

     

    9.10  Affiliates.
      Any
      licenses granted under this Agreement will be deemed to be granted both to
      a
      Party’s Affiliates, and by a Party’s Affiliates. Each Party shall cause its
      respective Affiliates to comply fully with the provisions of this Agreement
      to
      the extent such provisions specifically relate to, or are intended to
      specifically relate to, such Affiliates, as though such Affiliates were
      expressly named as joint obligors hereunder. For purposes of this Agreement,
      “Affiliate”
means
      any person, corporation, partnership or other entity that directly or indirectly
      controls or is controlled by or is under common control with a Party, where
      “control” is determined by direct or indirect ownership of fifty percent (50%)
      or more of the shares of stock entitled to vote for the election of directors,
      but excluding any parent entity that controls Genentech, including F. Hoffman
      La
      Roche, Ltd. and its successors (“Roche”), entities that control, are under
      common control (as defined in this Section) with any such parent entity, and
      any
      entities that are controlled by such parent entity other than through Genentech.
      

     

    9.11  Counterparts
      and Facsimile.
      This
      Agreement may be executed in two or more counterparts, each of which shall
      be
      deemed an original, but all of which together shall constitute one and the
      same
      instrument.

     

    9.12  Force
      Majeure.
      Neither
      Party shall be liable for failure of or delay in performing obligations set
      forth in this Agreement, and neither shall be deemed in breach of its
      obligations, if such failure or delay is due to natural disasters or any causes
      beyond the reasonable control of such Party. In event of such force majeure,
      the
      Party affected thereby shall use reasonable efforts to cure or overcome the
      same
      and resume performance of its obligations hereunder. 

     

    9.13  Non-Solicitation
      of Employees.
      During
      the term of this Agreement, Genentech shall not solicit any employee of
      ImmunoGen then performing Services (i.e.,
      [***]
      [***] has [***] on a [***] to [***] for the [***] or previous [***]) to
      discontinue his or her employment with ImmunoGen in order to become an employee
      or an independent contractor of Genentech; provided, however, that Genentech
      is
      not prohibited under this Section 9.13 from (a) employing any employee who
      contacts Genentech, directly or indirectly through an intermediary, at his
      or
      her own initiative without any solicitation by Genentech, or (b) placing an
      advertisement or making known an available job in any media, with any employment
      service or with a recruiter, provided such recruiters have not been directed
      to
      solicit employees of ImmunoGen who have performed Services under this
      Agreement.

     

    [Signature
      page follows.]

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the Parties have caused this PROCESS DEVELOPMENT AGREEMENT
      to
      be duly executed, effective as of the Effective Date, by their respective duly
      authorized officers.

     

    
      	
              GENENTECH, INC

            	
               

            	
              IMMUNOGEN, INC.

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
              By:

            	
               

            	
               

            	
              By:

            	
               

            
	
              Name:

            	
               Patrick Y. Yang, Ph.D.

            	
               

            	
              Name:

            	
              Pauline Jen Ryan

            
	
              Title:

            	
               Senior Vice President,

            	
               

            	
              Title:

            	
              Senior Vice President

            
	
               

            	
               Product Operations

            	
               

            	
               

            	
              Corporate Development and
                Operations

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
              Date:

            	
               

            	
               

            	
              Date:

            	
               

            
	
               

            	
               

            	
               

            	
               

            	
               

            

       

      
        
          
          

        

        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 24b-2 of the Securities Exchange Act of
              1934.

          

          
            

          

        

        
          
          

        

      

    

     

    Exhibit
      A: Project Document

    [***]
      [***] [***] Conjugation Process Development Project 

    

    The
      [***]
      [***] [***] Conjugation Process Development Project (the “Project”)
      with
      an effective date of May 3, 2006 is being undertaken under the PROCESS
      DEVELOPMENT AGREEMENT between ImmunoGen and Genentech dated as of May 3, 2006
      (the “Agreement”).
      The
      work plan is described in the following attachment. This is considered a
“Project Document” under the Agreement.

    

    

    Accepted
      and Agreed: 

     

    
      	
              GENENTECH, INC.

            	
               

            	
              IMMUNOGEN, INC.

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
              By:

            	
               

            	
               

            	
              By:

            	
               

            
	
              Name:

            	
               Patrick Y. Yang, Ph.D.

            	
               

            	
              Name:

            	
              Pauline Jen Ryan

            
	
              Title:

            	
               Senior Vice President,

            	
               

            	
              Title:

            	
              Senior Vice President

            
	
               

            	
               Product Operations

            	
               

            	
               

            	
              Corporate Development and
                Operations

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
              Date:

            	
               

            	
               

            	
              Date:

            	
               

            
	
               

            	
               

            	
               

            	
               

            	
               

            

       

      
        
          
          

        

        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 24b-2 of the Securities Exchange Act of
              1934.

          

          
            

          

        

        
          
          

        

      

    

    

    10.  Attachment
      1

     

    11.  Work
      Plan

     

    12.  Project
      Stages & Key Deliverables

     

    (Assumes
      a start date of May 3, 2006)

    

    
      	
              13.  stage

               

            	
              14.  description

               

            	
              15.  duration

               

            	
              16.  milestone

               

            	
              17.  date

               

            
	
              I

            	
              [***]
                [***] 

            	
              [***]
                - [***] [***]

            	
              [***]
                process [***]

              Process
                [***] [***] ([***])

              Process
                [***] [***] ([***])

            	
               

              [***]
                [***] [***], [***]

            
	
              II

            	
              [***]
                [***] [***]

            	
              [***]
                - [***] [***]

            	
              [***]
                [***]

            	
              [***]
                [***], [***]

            
	
              III

            	
              [***]
                [***] and [***]

            	
              [***]
                - [***] [***]

            	
              Final
                [***] × [***] [***]

            	
              end
                [***] [***]

            
	
              IV

            	
              [***]
                [***] to [***]

            	
              [***]
                [***]

            	
              Process
                [***] [***]

            	
              end
                [***] [***]

            

    

    18.  Project
      Timeline: Schedule

     

    
      	 	
              [***]

            	
              [***]

            	
              [***]

            
	 	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

              [***]

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              [***]
                [***] [***]

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              [***]
                [***] & [***]

            	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              [***]
                [***] 

              to
                [***] [***]

            	 	 	 	 	 	 	 	 	 	 	 	 	 

    

    19.  

     

    20.  Team
      Communication

     

     

    The
      joint
      development team expects to have weekly teleconferences and bimonthly face
      to
      face meetings or others as deemed necessary. A meeting agenda will be agreed
      to
      and provided prior to each meeting. Meeting slides and data will be provided
      prior to each meeting as needed. Meeting action items and follow up will be
      provided following each meeting as needed. The team will utilize a joint shared
      repository site to store project documents.

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    21.   Requirements
      & Scale

     

     

    [***]
      [***]: [***] or as [***] [***] by process [***] and equipment
      [***].

     

    Process
      [***]: The process used to generate the [***] [***] x [***] [***] should meet
      the following requirements:

    
      	1)  	
              Minimum
                [***] [***] per [***] should be >
[***]%

            

    

    
      	2)  	
              Process
                [***] for DM1 [***]

            

    

    
      	3)  	
              [***]
                [***] established (up to [***]
                cycles)

            

    

    
      	4)  	
              [***]
                [***] [***]

            

    

    
      	5)  	
              Process
                [***]:

            

    

    
      	a)  	
              [***]
                [***] [***]

            

    

    
      	b)  	
              [***]
                of [***] of [***] [***], removal of
                [***]

            

    

    
      	c)  	
              Process
                [***]

            

    

    
      	i)  	
              [***]
                and [***] [***]

            

    

    
      	ii)  	
              [***]
                [***] (to allow for [***] [***])

            

    

    

    Product
      [***]: The product should be [***] to the [***] [***] [***]. Product [***]
      [***]
      are:

    
      	1)  	
              [***]/[***]
                [***]: target = [***], range [***] to ≤
[***]

            

    

    
      	2)  	
              %
                [***]: > [***]%

            

    

    
      	3)  	
              [***]:
                same [***] as [***] [***], [***] [***] of [***] and
                [***]

            

    

    
      	4)  	
              [***]
                [***] ([***] to [***]): < [***]%

            

    

    
      	5)  	
              %
                [***] [***] upon [***]

            

    

    
      	a)  	
              [***]
                ([***] [***] [***] after [***] [***] by [***]-[***] [***]): <
                [***]%

            

    

    
      	b)  	
              [***]
                [***]: ≤ [***]% 

            

    

    
      	6)  	
              [***]
                by [***] [***] [***]: [***]

            

    

    NOTE:
      if
      [***] [***] is [***], then [***] will be [***], [***] [***]

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    22.  STAGE
      I: [***] [***]

     

    Purpose:  To
      define
      [***] [***] for the [***] [***] [***]. This includes the initial [***] of the
      [***] [***] [***] that [***] the [***] [***] and [***] [***] [***] equipment
      to
      be purchased by [***] [***] [***].

    

    Activities: 

    
      	1)  	
              [***]
                [***] - [***] will identify [***] [***] and [***] [***]. Factors
                that will
                be considered include [***] [***], [***] [***] and [***] of
                [***]

            

    

    
      	2)  	
              [***]
                [***] - [***] will perform the necessary studies to determine if
                [***] is
                sufficient for producing material with [***] [***] [***] [***] to
                enable a
                [***] vs. [***] decision. Factors evaluated will
                include

            

    

    
      	a)  	
              [***]
                [***] profile - Assess if [***] [***] during processing and determine
                if
                [***] [***] is needed. Demonstrate [***] [***] [***] that is consistent
                with a [***] process.

            

    

    
      	b)  	
              Data
                to support [***] of [***] [***] - Confirm [***] [***] for a minimum
                of
                [***] [***]

            

    

    
      	c)  	
              Evaluate
                potential effects on [***] [***] from [***] system elements ([***],
                [***],
                and [***]) that would be [***] of [***] [***] [***]
                equipment.

            

    

    
      	3)  	
              [***]
                [***] [***] - 

            

    

    
      	a)  	
              [***]
                will investigate and [***] as possible the [***] to [***] or other
                [***]
                assay to [***] [***] [***] as required by the [***]
                [***]

            

    

    
      	b)  	
              [***]
                [***] - IMGN and GNE will collaborate on development of suitable
                assay to
                monitor [***] and related [***]
                [***].

            

    

    
      	4)  	
              [***]
                [***]- to broadly understand impact of [***] [***] and
                [***].

            

    

    

    Deliverables

    GNE:     ·
[***]
      g
      [***]

           
      · Method for [***] [***]

           
      · Info on [***] [***]/[***]/[***]

           
      · [***] #[***] studies & # [***] as agreed by IMGN and GNE

                           
      · Final [***] (by month [***]) 

                           
      · [***] [***] not provided by [***] ([***] [***] [***], [***], [***] [***] and
      other [***] [***] methods)

    

    IMGN:           
      ·
      Laboratory [***] ([***] to [***])

           
      · [***] [***] reports

                           
      · [***] [***] [***] [***]

           
      · [***] Report

           
      · Draft [***] [***] [***] [***] method 

    

    

    Duration:      
      [***]
      [***]

    

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    23.  STAGE
      II: [***] [***] [***]

     

    Purpose:  To
      [***]
      process [***] at [***] [***]. This will be used to initiate [***] [***] of
      the
      [***] to the [***] [***].

     

    Activities:  [***]
      [***] × [***] [***] [***]

    

    

    Deliverables

    IMGN:     
      ·
[***]
      [***] [***] to facilitate [***] [***] ([***] [***] [***])

                     
      · Report
      containing [***] [***] (part of [***] [***] [***]), [***] [***] and [***] [***]
      [***] [***] that [***] and [***] meet [***] as indicated in the [***] and [***]
      section (summary of the [***] × [***] [***] [***]).

                     
      · [***]
      [***]

    

    Duration: [***]
      -
      [***] [***]

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

     

    24.  STAGE
      III: [***] [***] and [***]

     

    Purpose: To
      [***]
      the [***] and [***] that the [***] [***] is [***] and [***]. The goal is to
      [***] a [***] [***] to the [***] [***] that can be [***] [***] [***] [***]
      [***]
      [***] during routine [***].

    

    

    Activities: [***]
      will identify parameters that are [***] to the [***] and will [***] the [***]
      [***]. [***] [***] for each [***] [***], including [***] [***] will be
      evaluated. Studies will be done to [***] the [***] towards [***], to [***]
      the
      [***] of process [***] and to understand what [***] if the [***] [***] [***]
      [***] [***]. [***] [***] [***] [***] will be [***] to [***] [***] [***], [***]
      for [***], [***] [***] and [***] [***]. These [***] will serve as a [***] for
      [***] of the [***] to the [***] [***]. 

    

    Deliverables

    GNE:      
      ·
[***]
      [***] on [***] [***] and [***] [***]

                   
      · [***] [***] not provided [***] [***] ([***] [***] [***], [***], [***] [***]
      and other [***] [***] methods)

    

    Deliverables

    IMGN:   
      ·
[***]
      [***] [***] [***] (or as determined appropriate by [***] [***] and [***] [***],
      and meeting [***] as [***] in the [***] [***] of the [***] [***]
      [***])

    ·
[***]
      including [***] of [***] [***] [***] and [***] [***].

    ·
[***]
      [***]

    Weekly
      or
      biweekly updates as agreed to by both parties

    

    25.  Duration:[***]
      [***]

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    STAGE
      IV: [***] [***] to [***]

     

    Purpose:      
      To
      [***]
      the [***] [***] from [***] to the [***] [***].

          
      [***] will have overall responsibility to [***] [***]. [***] will provide [***]
      

                          
      [***] and is [***] [***] [***] [***] - [***] [***] to this
      activity.

    

    Activities:    
      [***]
      will support [***] to [***] the process to [***] [***] [***]. This will
      start

                           
      with [***] [***] [***] on [***] and will [***] with the [***] of [***] [***]
      [***] 

                           
      for the [***] [***] [***]. [***] will provide all the necessary [***] and [***]
      

                           
      [***] for the [***] of [***] [***].

    

    Deliverables: [***]
      [***] [***] of [***] [***] [***] required for [***] of [***] [***]
      [***].

    

    

    Duration: [***]
      [***]

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    26.  Total
      FTE Requirement at ImmunoGen 

     

    

    
      	
              First
                [***] months: 

            	 	
              [***]
                FTE in [***] [***] and [***]

            

    

    
      	 	 	
              [***]
                FTE in [***]

            

    

    
      	 	 	
              [***]
                FTE for [***] [***], [***] [***] 

            

    

    
      	 	 	
              [***]
                FTE Total on average

            

    

    

    Beyond
      first [***] months:  [***]
      -
      [***] FTE until completion of activities (completion expected end of
      [***])

    

    

    Estimated
      FTEs by [***]

    

    The
      estimated [***] and cumulative FTE-based Services fees are listed below,
      assuming project initiation on [***] [***], 2006. A range has been estimated
      for
      the period after [***] [***] until [***] of [***] to the [***] to [***] [***]
      over the activities for this phase. 

    

    
      	
              [***]
                

            	
              FTE’s
                Allocated 

            	
              Estimated
                [***] FTE Fee

            	
              Cumulative
                FTE Fee

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***] 

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]

            	
              $[***]

            	
              $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            
	
              [***]
                [***]

            	
              [***]
                - [***]

            	
              $[***]
                - $[***]

            	
              $[***]
                - $[***]

            

    

    

    

    Estimated
      Materials Requirements

    [***]:
      [***] [***]

    [***]:
      [***] - [***] [***]

    [***]:
      [***] - [***] [***]

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      B: PRESS RELEASE

    

    ImmunoGen,
      Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1
      for
      Genentech

     

    -Companies
      also amend 2000 agreement for TAP compounds targeting HER2, potentially
      providing increased royalties and milestones to ImmunoGen -

     

    CAMBRIDGE,
      MA, May 4, 2006-
      ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops
      targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP)
      technology, today announced that the Company has entered into an agreement
      to
      collaborate with Genentech to create a commercial manufacturing process for
      Genentech’s trastuzumab-DM1 TAP compound. ImmunoGen and Genentech also have
      agreed to amend their 2000 agreement that grants Genentech exclusive rights
      to
      use ImmunoGen’s TAP technology with therapeutic antibodies to HER2. This
      amendment increases the total potential milestone payments to ImmunoGen under
      this agreement to $44 million and the royalties to ImmunoGen on
      HER2-targeting TAP compounds developed by Genentech, including
      trastuzumab-DM1.

    

    “We’re
      delighted that Genentech chose to access our process development expertise
      in
      order to gain a commercial-scale manufacturing process for trastuzumab-DM1,”
commented Mitchel Sayare, Chairman and CEO. “We believe that the considerable
      increase in the milestone payments and royalties that ImmunoGen potentially
      can
      earn with Genentech’s successful development of HER2-targeting TAP compounds
      reflects the value of our manufacturing expertise in this area as well as the
      significance of our technology.” 

    

    Under
      the process development agreement announced today, ImmunoGen and Genentech
      will
      develop a production method for Genentech to manufacture trastuzumab-DM1 at
      amounts up to and including commercial scale, and ImmunoGen will receive
      research support payments in return. ImmunoGen
      and Genentech also have amended the 2000 agreement that
      grants Genentech exclusive rights to use ImmunoGen’s maytansinoid TAP technology
      with therapeutic antibodies to HER2.
      This
      amendment increases the potential milestone payments to ImmunoGen under this
      agreement by $6.5 million and the potential royalties to ImmunoGen on any
      HER2-targeting TAP compound that may be developed by Genentech. 

    

    A
      TAP
      compound uses a tumor-targeting antibody to deliver a potent, cell-killing
      agent
      specifically to cancer cells. During the manufacturing process, the cell-killing
      agent is attached to the antibody in a manner that does not significantly impact
      the binding properties of the antibody. In the past
      few years, ImmunoGen has manufactured numerous TAP compounds for
      preclinical and initial clinical testing at the Company's production facility
      in
      Norwood, MA. ImmunoGen developed each production method used, providing the
      Company with extensive experience in the development of manufacturing processes
      for TAP compounds.

    

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    About
      ImmunoGen, Inc. 

    

    ImmunoGen,
      Inc. develops targeted anticancer biopharmaceuticals. The Company’s proprietary
      TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing
      agent specifically to cancer cells. Four TAP compounds are in clinical testing
      -
      huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633
      and
      trastuzumab-DM1, which are in development by the sanofi-aventis Group and
      Genentech, respectively. The sanofi-aventis Group, Genentech, Centocor, Biogen
      Idec, Boehringer Ingelheim, Millennium Pharmaceuticals, Inc., and Amgen
      (formerly Abgenix), have licensed the right to develop and/or test TAP compounds
      to specific targets; ImmunoGen also has a broader collaboration with the
      sanofi-aventis Group. 

    

    This
      press release includes forward-looking statements. For these statements,
      ImmunoGen claims the protection of the safe harbor for forward-looking
      statements provided by the Private Securities Litigation Reform Act of 1995.
      It
      should be noted that there are risks and uncertainties related to the Company’s
      development of its own products, as well as to the development of products,
      including trastuzumab-DM1, by our collaborators. A review of these risks can
      be
      found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June
      30, 2005 and other reports filed with the Securities and Exchange
      Commission.

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.Exhibit 10.32

    Amendment
      to License Agreement for Anti-HER2
      Antibodies

     

    Genentech, Inc.
      (“GENENTECH”) and ImmunoGen, Inc.
      (“IMMUNOGEN”) are entering into this Amendment to License
      Agreement for Anti-HER2 Antibodies (“Amendment”) as of May 3,
      2006 (the “Amendment Effective Date”). 

     

    Background

     

               
Genentech and ImmunoGen
      are parties to the following agreements: that certain
      License Agreement dated as of May 2, 2000, and amendments thereto (the
“License Agreement”); that certain Heads of Agreement, dated as
      of May 2, 2000, as amended (as so amended, the “Heads of
      Agreement”); that certain Process Development Heads of Agreement, dated
      as of June 29, 2001, and amendments thereto, including that certain Amendment
      No.1 dated November 15, 2002 (the “PD Heads of Agreement”);
      that certain Manufacturing and Supply Agreement dated as of January 11, 2005,
      and amendments thereto (the “Clinical Supply Agreement”); that
      certain Development Agreement dated as of June 1, 2004, and amendments thereto
      (the “Development Agreement”); and the Quality Services
      Agreement dated as of June 30, 2005 (the “Quality Services
      Agreement”) (the License Agreement, the Heads of Agreement, the PD
      Heads of Agreement, the Clinical Supply Agreement, the Development Agreement
      and
      the Quality Services Agreement, collectively the “Existing
      Agreements”).  

     

               
GENENTECH and IMMUNOGEN
      are, as of the Amendment Effective Date, entering into a
      Process Development Agreement (the “Process Development
      Agreement”), under which IMMUNOGEN will develop a commercial-scale
      conjugation process for certain products that are “Licensed Products” under the
      License Agreement. 

     

               
In connection with entering
      into the Process Development Agreement, GENENTECH
      has agreed to increase the milestones and royalties for Licensed Products in
      certain circumstances, as set forth in this Amendment. 

     

               
GENENTECH and IMMUNOGEN
      also have agreed to modify the terms of the license
      granted, specifically by revising the definition of “Improvements” and expanding
      IMMUNOGEN’s rights to Improvements. 

     

             In
      consideration of the mutual promises and covenants contained in this Amendment,
      the sufficiency of which consideration is hereby mutually acknowledged, the
      Parties have agreed as follows:

     

    Agreement

     

    1.      Definitions. 
      In the License Agreement, the following definitions are modified or added,
      effective as of the Amendment Effective Date.

    (a)       
      Definition of “Improvement.”  Section 1.27 (definition
      of “Improvement”) of the License Agreement is hereby deleted in its entirety and
      replaced with the following: 

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    1.27    
      “Improvement” means: (a) improvements to any MAY Compound,
      (b) improvements to methods of making any MAY Compound, and
      (c) improvements to the conjugation process for making antibody-drug
      conjugates that include any MAY Compound (including, for example, reaction
      conditions or changes in process that create improvements in the yield of such
      conjugate).  “Improvement” excludes any and all of the following items
      (“GNE Exclusions”): (w) any improvement that is specific to any
      antibody-drug conjugates that bind to an antigen that is subject to an exclusive
      license from ImmunoGen under, or arising from, the Heads of Agreement or is
      subject to an Exclusive Target Option under the Heads of Agreement during the
      period that such exclusive license or Exclusive Target Option remains in effect;
      (x) improvements to [***] [***] [***] or [***] [***], or the [***] of [***]
      or [***] [***] of the foregoing; (y) improvements arising out of Genentech
      [***] or [***] activities (whether or not the associated [***] is licensed
      to
      Genentech by ImmunoGen); or (z) the [***] or [***] of [***] [***] [***]
      (i.e., the [***] or [***] of such [***] [***] (e.g., the [***] of
      [***] or the [***] of [***] to [***]) and [***] the manner of [***] such [***]
      [***]) that binds to an antigen that is subject to an exclusive license from
      ImmunoGen under, or arising from, the Heads of Agreement or an antigen that
      is
      subject to an Exclusive Target Option under the Heads of Agreement, during
      the
      period that such exclusive license or Exclusive Target Option remains in
      effect.

     

    (b) 
            Definition of “ImmunoGen
      Field.” A new Section 1.26A is added as follows:  

     

         
      1.26A        “ImmunoGen
      Field” means any and all uses other than any use that involves
      an antibody that binds to an antigen that is subject to an exclusive license
      from ImmunoGen under, or arising from, the Heads of Agreement or an antigen
      that
      is subject to an Exclusive Target Option under the Heads of Agreement, during
      the period that such exclusive license or Exclusive Target Option remains in
      effect.

     

    2.       License
      to ImmunoGen.  Section 2.1(b) of the License Agreement is hereby
      deleted in its entirety and the following is inserted in lieu thereof: 

       

    (b)      
      License to IMMUNOGEN.  GENENTECH hereby grants to IMMUNOGEN a
      non-exclusive, royalty-free license (i) under GENENTECH’s    

    intellectual
      property interest in Improvements, to develop, make, use, sell, offer for sale,
      import, and export any product that is not a Licensed Product, subject to
      Section 2.3(b) below and the remaining terms of this Section 2.1(b); and (ii)
      to
      otherwise exploit Improvements for all uses within the ImmunoGen Field, subject
      to Section 2.3(b) below and the remaining terms of this Section 2.1(b). 
The foregoing license includes the right to sublicense the rights granted under
      this Section 2.1(b) on and after the Amendment Effective Date
      only if all of the following three conditions (i), (ii) and (iii) are met:
      

    (i)        
      the sublicense is limited to the ImmunoGen Field; 

          (ii)       
      the sublicense is granted only in connection with a license to ImmunoGen MAY
      Technology (where “ImmunoGen MAY Technology” means Technology
      Controlled by ImmunoGen and used in the conjugation of MAY Compounds to binding
      proteins), and the rights granted for ImmunoGen MAY Technology are of the same
      scope (e.g., for the same product or technology and within the same field and
      the same territory) as the rights granted for Genentech’s Improvements;
      and

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

          (iii)      
      GENENTECH obtains Substantially Similar Grant Back Rights without incurring
      an
      obligation to pay any additional consideration (either to IMMUNOGEN or to the
      sublicensee).   “Substantially Similar Grant Back Rights” means
      non-exclusive rights in and to that sublicensee’s “improvements” (improvements
      to MAY Compounds, methods of making MAY Compounds, and methods of making
      antibody-drug conjugates) that are of substantially the same scope (e.g., within
      the same field and the same territory) as the rights granted in and to
      Improvements under this Agreement.  (GENENTECH may obtain such rights
      directly from IMMUNOGEN’s sublicensee or indirectly through IMMUNOGEN; if
      GENENTECH obtains such rights from IMMUNOGEN, IMMUNOGEN may have obtained such
      rights under license or by transfer of ownership).

     

    Nothing
      in this Agreement or the course of dealings between the Parties or usage or
      custom in the industry or trade shall be construed to confer any other rights
      or
      licenses to any other intellectual property Controlled by either Party or its
      Affiliates by implication, estoppel or otherwise.  GENENTECH has no
      obligation to [***] in any [***] [***] or [***] of [***] [***] to [***] or
      a
      [***] of [***] with respect to [***]. During the term of the Process Development
      Agreement, IMMUNOGEN may inquire of GENENTECH as to Improvements Controlled
      by
      GENENTECH, and GENENTECH shall respond by disclosing any such Improvements
      within the ImmunoGen Field.  

     

    3.      Milestone
      Payments.  Section 4.1.1 of the License Agreement is replaced in
      its entirety by the following: 

     

    4.1.1   
      In consideration of the grant of the license by IMMUNOGEN hereunder, and subject
      to the other terms of this Agreement, GENENTECH will pay IMMUNOGEN the amounts
      in the column titled “milestone payment” within thirty (30) days after the first
      achievement of each of the milestones set forth in the table below. 
Further, if IMMUNOGEN successfully meets the milestones set forth in the Process
      Development Agreement and if the [***] of the Conjugation Process (as defined
      in
      the Process Development Agreement) to a [***] is [***] by the end of the first
      [***] [***] of [***] (as the foregoing timeline will be adjusted in accordance
      with the Process Development Agreement), then GENENTECH shall pay IMMUNOGEN
      the
      amounts in the column titled “additional payment” within thirty (30) days after
      the first achievement of the milestones for which an additional payment applies.
       Milestone payments and additional payments under this Section are
      nonrefundable and noncreditable, except as expressly provided in Section 4.1.2
      below. 

     

    
    

    
      	
              Milestone

            	
              Milestone
                Payment

            	
              Additional
                Payment

            
	
              Effective
                Date (of License Agreement)

            	
              $2
                Million*

            	
               

            
	
              IND
                Acceptance for a Licensed Product

            	
              $2
                Million*

            	
               

            
	
              [***]
                of [***] [***] [***] [***] [***] [***] [***] for a [***] [***]

            	
              $[***]
                [***]

            	
              $[***]
                [***]

            
	
              [***]
                of [***] [***] [***] [***] in the [***] [***] for a [***] [***] or
                [***]
                [***] [***] [***] for a [***] [***] ([***] is [***])

            	
              $[***]
                [***]

            	
              $[***]
                [***]

            
	
              [***]
                of [***] or [***] by the [***] for a [***] [***] for [***] of [***]
                [***]
                [***]

            	
              $[***]
                [***]

            	
              $[***]
                [***]

            
	
              [***]
                of an [***] or other [***] [***] [***] in the [***] [***] for a [***]
                [***] for [***] of [***] [***] [***]

            	
              $[***]
                [***]

            	
               

            
	
              [***]
                of a [***] [***] for a [***] [***] in [***] for treatment of [***]
                [***]
                [***]

            	
              $[***]
                [***]

            	
               

            
	
              [***]
                of [***] or [***] by the [***] for a [***] [***] [***]

            	
              $[***]
                [***]

            	
               

            
	
              [***]
                of [***] or [***] by the [***] for [***] [***] [***].

            	
              $[***]
                [***]

            	
               

            

    

     

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

    It
      is hereby acknowledged and agreed that those milestone payments and
      additional payments identified with a * in the table above already have been
      paid by GENENTECH.  It is also hereby acknowledged and agreed that any
      milestone payment shall be made only once, with respect to the first achievement
      of the relevant milestone for the first Licensed Product, regardless of how
      many
      times a particular Licensed Product achieves such milestones.  GENENTECH
      shall notify IMMUNOGEN of the achievement of milestones hereunder as provided
      in
      Section 3.2(a) above. 

     

    4.      Royalties. 
      Section 4.2.3 ([***] [***] [***]) of the License Agreement is replaced with
      the
      following: 

     

    4.2.3   
[***]
      [***] [***].  In
      consideration of the grant of the license by IMMUNOGEN hereunder, and subject
      to
      the other terms of this Agreement (including the other terms of this Section
      4):

     

             (a) 
      [***] [***] [***].  Notwithstanding anything set forth in [***]
      above, the [***] [***] set forth therein shall apply, on a [***] and [***]
      [***], to [***] [***] of [***] [***] [***] [***] [***] [***] [***] or its [***],
      [***] or [***] in [***] [***] would, [***] for the [***] under this Agreement,
      [***] a [***] [***] [***] the [***] [***] [***] (excluding any [***] [***]
      [***]
      [***] by [***] and [***] and further excluding any [***] [***] in or to [***]
      for which [***] is the [***] or [***] [***]).Subject to the other
      terms of this Agreement (except for Section 4.2.2 above, which shall not apply),
      on a [***] and [***] [***] where and as of when the [***] [***] under Section
      4.2.1 [***] [***] [***] as a [***] of this Section 4.2.3 (a), GENENTECH shall
      [***] to IMMUNOGEN a [***] [***] to [***]:

                          
      (i) if the [***] [***] has been [***] [***], in [***] or in [***] [***], the
      [***] [***] (as defined in the Process Development Agreement) following the
      [***] of the [***] [***] the [***] [***] as contemplated by Section 3.2 of
      the
      Process Development Agreement, then [***] [***] ([***]) of [***] [***] of [***]
      [***] [***] [***] by [***] and/or its [***] in [***] [***];
      or 

    (ii) 
if
      the [***] [***] has not been [***] [***],
      in [***] or in [***] [***], the [***] [***] (as defined in the Process
      Development Agreement) following the [***] of the [***] [***] the [***] [***]
      as
      contemplated by Section 3.2 of the Process Development Agreement, then [***]
      [***] ([***]) of [***] [***] of [***] [***] [***] [***] by [***] and/or its
      [***] in [***] [***]. 

     

    5.        
      Miscellaneous.  This Amendment is governed by the
      substantive rules of the state of California.  Capitalized terms used and
      not otherwise defined herein shall have the respective meanings ascribed to
      them
      in the respective Existing Agreement that is being amended hereby.  
The Existing Agreements remain in full force and effect, as amended by this
      Amendment.  References in the Existing Agreements to “Agreement” mean those
      Existing Agreements as amended by the Amendment. 

     

    [Signature
      page follows.]

    
      
        
        

      

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

     

     

    
      IN WITNESS WHEREOF,
        the
        Parties have caused this AMENDMENT TO LICENSE AGREEMENT to be duly executed,
        effective as of the Amendment Effective Date, by their respective duly
        authorized officers. 

       

      
      

      	
              GENENTECH, INC.

            	
               

            	
              IMMUNOGEN, INC.

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
              By:

            	
               

            	
               

            	
              By:

            	
               

            
	
              Name:

            	
               

            	
               

            	
              Name:

            	
              Pauline Jen Ryan

            
	
              Title:

            	
            	
               

            	
              Title:

            	
              Senior Vice President

            
	
               

            	
               

            	
               

            	
               

            	
              Corporate Development and
                Operations

            
	
               

            	
               

            	
               

            	
               

            	
               

            
	
              Date:

            	
               

            	
               

            	
              Date:

            	
               

            
	
               

            	
               

            	
               

            	
               

            	
               

            

       

       

       

      
        
          
          

        

        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 24b-2 of the Securities Exchange Act of
              1934.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]